James Lang
About James Lang
James Lang (age 60) serves as Chairman of the Board (since 2023) and director (since 2016) at BioVie Inc.; he is designated independent under Nasdaq standards and qualifies as an Audit Committee Financial Expert. He is CEO of EVERSANA and previously served as CEO of Decision Resources Group and IHS Cambridge Energy Research Associates, and President of Strategic Decisions Group; he holds a BS in Electrical & Computer Engineering (University of New Hampshire) and an MBA from Tuck School of Business. He also serves as a director at OptimizeRX (Nasdaq: OPRX) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| EVERSANA | Chief Executive Officer | Current; EVERSANA now >$1B revenue, ~7,000 employees across 40 sites | Commercialization leadership; scale and operational expertise |
| Decision Resources Group (DRG) | Chief Executive Officer | Former | Transformed DRG into leading healthcare data/analytics firm |
| IHS Cambridge Energy Research Associates (IHS CERA) | Chief Executive Officer | Former | Led energy subscription information products business |
| Strategic Decisions Group (SDG) | President | Former | Global strategy consultancy leadership |
External Roles
| Organization | Role | Public/Private | Potential Interlock/Exposure |
|---|---|---|---|
| OptimizeRX (OPRX) | Director | Public | No related-party transactions disclosed with BioVie |
| EVERSANA | Chief Executive Officer | Private | Commercialization services provider; no related-party transactions disclosed with BioVie |
Board Governance
- Independence: The Board determined Mr. Lang is independent under Nasdaq rules .
- Roles: Chairman of the Board; Chairman, Audit Committee; Member, Compensation Committee; proxy nominee profile lists him as Member, Nominating & Corporate Governance (committee roster shows Nominating & Corporate Governance composed of Chappell, Rogich, Sherman) .
- Audit Committee Financial Expert: Mr. Lang qualifies under Item 401(h)(2) of Regulation S‑K .
- Attendance: FY2025—Board 7 meetings; Audit 4; Compensation 2; Nominating & Corporate Governance 1; all directors attended ≥75% of meetings of the Board and committees on which they served .
- 2025 Shareholder Voting: James Lang elected with 1,513,727 “For” and 39,621 “Withhold”; strong support with standard broker non‑vote .
- Anti‑hedging: Insider trading policy restricts derivatives and short sales .
Committee Assignments
| Committee | Role | Notes |
|---|---|---|
| Audit | Chair; Financial Expert | Independent; oversees auditor and financial reporting; signed Audit Committee Report as Chair |
| Compensation | Member | Reviews CEO pay and director remuneration policies |
| Nominating & Corporate Governance | Member (per nominee profile) | Committee roster lists Chappell, Rogich (Chair), Sherman; membership discrepancy noted |
Fixed Compensation
| Year | Annual Retainer / Cash Fees (USD) | Committee Chair Fees (Cash) | Committee Member Fees (Cash) | Meeting Fees (Cash) |
|---|---|---|---|---|
| FY2025 | $13,750 | — (not separately disclosed) | — (not separately disclosed) | — (not separately disclosed) |
Performance Compensation
| Year | RSU Grants (Fair Value, USD) | Option Awards (Fair Value, USD) | Award Type Details | Vesting / Performance Terms |
|---|---|---|---|---|
| FY2025 | $0 | $157,204 | Directors could elect RSUs or options; program under 2019 Plan | 2019 Plan has no automatic CIC acceleration; vesting per award agreements; committee discretion on treatment |
| FY2025 Program Features | — | — | For those choosing options: committee chair 470 options; committee member 240 options; aggregate director grants totaled 28,137 options (fair value $490,797) or 6,690 RSUs (grant value $224,784) | Plan permits performance awards but director equity in FY2025 was RSUs/options; no director performance metrics disclosed |
Note: The proxy describes three option‑electing directors with role‑based grant sizes (e.g., one director received 6,160 options for serving as Chairman and on two committees, one of which he chaired), but does not name recipients; James Lang’s role profile matches the described Chairman scenario, however the filing does not explicitly attribute counts to him .
Other Directorships & Interlocks
| Company | Role | Committee Roles | Potential Conflict Check |
|---|---|---|---|
| OptimizeRX (OPRX) | Director | Not disclosed | No related‑party transactions with BioVie (≥$120k or ≥1% assets) since July 1, 2024 |
| EVERSANA | CEO | N/A | Could be a supplier/partner to biopharma; BioVie discloses no related‑party transactions with directors/officers in period |
Expertise & Qualifications
- Financial oversight: Audit Committee Financial Expert; signed FY2025 Audit Committee report .
- Industry experience: Lifesciences commercialization (EVERSANA), healthcare data/analytics (DRG), energy industry information (IHS CERA), strategy consulting (SDG) .
- Education: BS summa cum laude in Electrical & Computer Engineering (UNH); MBA with Distinction (Tuck) .
Equity Ownership
| Holder | Common Shares Beneficially Owned | Percent of Outstanding | Options Exercisable within 60 days | RSUs Exercisable within 60 days |
|---|---|---|---|---|
| James Lang | 10,810 | <1% | 10,120 | — (none listed for Lang) |
Ownership table based on 7,535,080 shares outstanding as of September 22, 2025 .
Insider Filings / Trades
| Person | Section 16(a) Disclosure | Note |
|---|---|---|
| James Lang | Form 4 filed January 7, 2025 (timing noted among late filings list) | Indicates a late filing occurrence in FY2025; specific transaction details not enumerated in proxy |
Governance Assessment
-
Strengths:
- Independent Chairman of the Board with deep commercialization and strategy experience; designated Audit Committee Financial Expert and active Audit Chair (signed FY2025 report) .
- Strong shareholder support in 2025 election (1,513,727 “For”; modest withhold) .
- Board/committee attendance thresholds met across FY2025; regular committee activity (Board 7; Audit 4; Compensation 2; Nominating 1) .
- No related‑party transactions with directors/officers disclosed during period; Audit Committee pre‑approves related party transactions .
-
Alignment & incentives:
- Director equity chosen as options for Mr. Lang in FY2025 (fair value $157,204) alongside modest cash fees ($13,750), indicating at‑risk equity exposure; options exercisable within 60 days total 10,120, with overall beneficial ownership <1% .
- Anti‑hedging policy in place restricting derivative/short sales .
-
Risks and RED FLAGS:
- Section 16 late filing noted for James Lang (Jan 7, 2025), a compliance blemish; monitor ongoing filing timeliness. RED FLAG .
- 2019 Plan allows potential excise tax “gross‑up” provisions in award agreements upon change‑of‑control (discretionary, not stated as used); shareholders generally view gross‑ups unfavorably. RED FLAG (potential if applied) .
- Committee membership disclosure discrepancy (Lang listed as Nominating member in nominee profile, but roster shows Nominating & Corporate Governance members as Chappell, Rogich, Sherman); clarity on current assignment advisable. Process clarity risk .
- Multiple external leadership commitments (CEO of EVERSANA, director at OPRX) could pose time‑commitment risk; however, attendance thresholds were met in FY2025. Monitoring point .
- No disclosure of director stock ownership guidelines or pledging policies for directors beyond anti‑hedging; ownership guidelines would enhance alignment transparency .
-
Signals for investors:
- Audit leadership and financial expert designation plus clean related‑party profile supports governance confidence .
- Equity plan expansion (approved Nov 10, 2025) increases capacity for equity alignment across directors/executives; no automatic acceleration on CIC reduces windfall risk .